Bifidobacterium bifidum in relation to the treatment of diabetes and related diseases

Abstract

Provided is a Bifidobacterium bifidum strain ibiome00l, which can significantly reduce the body weight and the weight of white fat in high-fat diet-induced obese diabetic mice, and enhance the expression of lipolysis genes ATGL and HSL. In addition, it significantly reduced the fasting blood glucose, the area under the curve of the oral glucose tolerance test, the plasma glycated hemoglobin and the insulin content in the mice. This strain is a potential functional strain for treating metabolic syndromes such as obesity and diabetes, and is more effective than combinations with other Bifidobacterium bifidum.

Description

Technical Field

[0001] The present invention belongs to the field of microbial technology, and specifically relates to Bifidobacterium bifidum for the treatment of diabetes and related diseases.

Background Art

[0002] With the development of society, people's living standards have improved and their diet structures have been adjusted. During this process, diets tend to be enriched, and high-fat diets containing a lot of fish and meat have become an important daily diet style. However, this has led to an increase in the incidence of metabolic diseases. In particular, metabolic syndromes such as obesity and diabetes are the most common, having a profound impact on people's physical and mental health.

[0003] There are about 1.5 kg of bacteria in the intestine, and the huge intestinal flora forms a close structural and functional relationship through long-term coevolution with the host. The intestinal flora contributes to the homeostasis balance of the host through a series of functions such as digestion of nutritional components, supply of vitamins and energy to the host, and participation in the construction of normal immunity. The imbalance of the intestinal flora is considered to be related to more than 50 types of diseases. In recent research, it has been discovered that metabolic diseases, especially obesity and diabetes, are closely related to the intestinal flora, and the intestinal flora can regulate the host's fat accumulation and insulin sensitivity. In clinical FMT research, it has been shown that insulin resistance was significantly improved after obese patients received intestinal FMT from normal individuals for 6 weeks. In another study, in the research on the intestinal flora of 171 Chinese adult type 2 diabetes patients and 174 healthy volunteers, a total of 52,484 intestinal bacterial genes related to type 2 diabetes were identified. Therefore, probiotics have great potential in the treatment of obesity and diabetes.

[0004] GPR120 is a long-chain unsaturated free fatty acid receptor with various physiological functions, including regulating the secretion of gastrointestinal hormones and the development and differentiation of adipocytes. Animal studies have shown that a high-fat diet causes more severe obesity, insulin resistance, and hepatic steatosis in GPR120-deficient mice. A series of preclinical studies have shown that GPR120 agonists can regulate glucose and energy homeostasis, including improving chronic inflammation and insulin resistance associated with obesity, regulating adipocyte thermogenesis, and regulating appetite. Human cohort studies have also shown that the R270H mutation in the GPR120L amino acid sequence is significantly associated with obesity. Therefore, GPR120 is a potentially important target in the treatment of metabolic syndrome, such as obesity and diabetes.

[0005] Adipose tissue contains two types of triglyceride lipases: adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL). The former is very important in basic lipolysis and is the main lipolytic enzyme because it is active without requiring hormonal activation. The latter needs to be activated by lipolytic hormones. The triglycerides (TG) that both enzymes hydrolyze account for approximately 95% of the total hydrolysis.

[0006] HSL was discovered in 1962 and was given its name because its lipase activity is greatly influenced by hormones. Research shows that HSL activators phosphorylate HSL via PKA and transfer it to lipid droplets, thereby promoting lipolysis. Insulin is the most important inhibitor of this process.

[0007] ATGL was discovered in 2004. Because its C-terminus contains a hydrophobic lipid droplet binding region, it primarily positions itself on the surface of lipid droplets. ATGL can specifically hydrolyze the first ester bond of TG and is considered the rate-limiting enzyme in TG hydrolysis. A decrease in its expression leads to a massive accumulation of TG in adipocytes and other tissues, causing obesity and other metabolic complications. [Overview of the project] [Problems that the invention aims to solve]

[0008] The object of the present invention is to provide Bifidobacterium bifidum for use in the treatment of diabetes and related diseases. [Means for solving the problem]

[0009] This invention is realized by the following technical means. Bifidobacterium bifidum ibiome001 is preserved at the Guangdong Provincial Microbial Species Preservation Center, located at "5th Floor, Building 59, Dayuan, 100 Xianlie Middle Road, Guangzhou, Guangdong Province, Guangdong Provincial Academy of Sciences, Institute of Microbiology." The preservation date is May 17, 2022, and the preservation number is GDMCC No. 62473. The whole genome sequence is shown as SEQ ID NO.2.

[0010] Bifidobacterium bifidum ibiome001 contains at least one specific gene fragment or its complementary fragment within SEQ ID NO.2-5.

[0011] The present invention relates to the use of the above-mentioned Bifidobacterium bifidum ibiome001 and its metabolites, or a mixture containing the bacterium and / or its metabolites, in the manufacture of a functional bacterial agent or pharmaceutical product. mammal Protect the use of the following (a) through (j) for the prevention or treatment of one or more diseases and conditions: (a) Diabetes (b) Metabolic syndrome (c) Abnormalities in glycated hemoglobin (d) Abnormal insulin sensitivity (e) Abnormal fasting blood glucose levels (f) Abnormal oral glucose tolerance (g) Abnormal fasting insulin levels (h) Obesity (i) Weight gain (j) Increased weight of adipose tissue.

[0012] The present invention protects the use of Bifidobacterium bifidum ibiome001 and its metabolites, or mixtures containing the bacterium and / or its metabolites, in the manufacture of functional bacterial agents or pharmaceuticals that activate GPR120.

[0013] The present invention protects the use of Bifidobacterium bifidum ibiome001 and its metabolites, or mixtures containing the bacterium and / or its metabolites, in the manufacture of functional bacterial agents or pharmaceuticals that enhance the expression of lipolytic genes ATGL and / or HSL.

[0014] Furthermore, the aforementioned diabetes is type 2 diabetes.

[0015] Furthermore, the aforementioned mammal is a high-fat diet mammal.

[0016] The present invention protects the use of the above-mentioned Bifidobacterium bifidum ibiome001 and its metabolites, or mixtures containing the bacterium and / or its metabolites, in the manufacture of food or nutritional supplements.

[0017] The present invention also protects compositions comprising Bifidobacterium bifidum ibiome001 or its metabolites, and compositions comprising pharmaceutically acceptable carriers.

[0018] Furthermore, the pharmaceutically acceptable carrier includes one or more of fillers, binders, wetting agents, disintegrants, lubricants, flavoring agents, diluents, and absorption enhancers that are commonly used in medicine.

Advantages of the Invention

[0019] The beneficial effects of the present invention are as follows. Bifidobacterium bifidum ibiome001 of the present invention can significantly reduce the body weight and the weight of white fat in obese and diabetic mice induced by a high-fat diet, and enhance the expression of lipolysis genes ATGL and HSL. In addition, it can significantly reduce the fasting blood glucose, the area under the curve of the oral glucose tolerance test, the glycated hemoglobin and insulin content in plasma of mice. Bifidobacterium bifidum ibiome001 is a potential functional strain in the treatment of metabolic syndromes such as obesity and diabetes, and is more effective than combinations with other Bifidobacterium bifidum.

[0020] Biological preservation For Bifidobacterium bifidum ibiome001, the preservation date is May 17, 2022, the preservation place is the Guangdong Provincial Center for Microbial Culture Collection, the address is the 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou City, Guangdong Province, Institute of Microbiology, Guangdong Academy of Sciences, and the preservation number is GDMCC No. 62473.

Brief Description of the Drawings

[0021] [Figure 1] It is a microscopic photograph (40X) of a smear specimen of ibiome001 of the present invention. [Figure 2] It is the form of the colony formed by ibiome001 of the present invention on a solid medium. [Figure 3] It is a genetic comparison diagram between ibiome001 of the present invention and other Bifidobacterium bifidum. [Figure 4] This is an enlarged view of SEQ ID NO. 2 of the gene comparison between ibiome001 of the present invention and two other Bifidobacterium bifidum. [Figure 5] This is an enlarged view of SEQ ID NO. 3 of the gene comparison between ibiome001 of the present invention and two other Bifidobacterium bifidum. [Figure 6] This is an enlarged view of SEQ ID NO. 4 of the gene comparison between ibiome001 of the present invention and two other Bifidobacterium bifidum. [Figure 7] This is an enlarged view of SEQ ID NO. 5 of the gene comparison between ibiome001 of the present invention and two other Bifidobacterium bifidum. [Figure 8] This result shows that different strains of Bifidobacterium bifidum activate GPR120. [Figure 9] The present invention shows the effects of ibiome001 and three other control groups on the body weight of obese and diabetic mice, where a represents the percentage change in body weight, b represents the body weight value, * indicates P<0.05, and ** indicates P<0.01. [Figure 10] The present invention shows the effects of ibiome001 and three other control groups on blood glucose levels in obese and diabetic mice, where * indicates P<0.05. [Figure 11] The effects of ibiome001 and three other control groups of the present invention on oral glucose tolerance tests (OGTT) and area under the curve (AUC of OGTT) in obese and diabetic mice are shown, with * indicating P<0.05. [Figure 12] The effects of ibiome001 and three other control groups on the fat content of obese and diabetic mice are shown, where * indicates P<0.05 and ** indicates P<0.01. [Figure 13] The present invention shows the effects of ibiome001 and three other control groups on lipolysis gene expression in white fat of obese and diabetic mice, where * indicates P<0.05. [Figure 14]The present invention shows the effects of ibiome001 and three other control groups on the glycated hemoglobin content of obese and diabetic mice, where ** indicates P<0.01. [Figure 15] The effects of ibiome001 and three other control groups of the present invention on the plasma insulin content of obese and diabetic mice are shown, where * indicates P<0.05 and ** indicates P<0.01. [Modes for carrying out the invention]

[0022] To better understand the present invention, it will be further described below with reference to examples and drawings. The following examples illustrate the present invention and are not limiting. Unless otherwise specified, all conditions and procedures not specifically described are general methods, and the reagents and materials used are commercially available.

[0023] Example 1: Isolation and identification of bacterial strains 1 separation Stool samples were taken from 10 healthy volunteers, stored in 20% volume glycerophosphate buffer, and each stool sample was divided into 10 portions. -5 , 10 -6 , 10 -7 Dilute it gradually. Each concentration was spread onto MRS broth medium (Solarbio, catalog number M8540) and incubated anaerobically at 37°C for 48 hours. The monoclonal cells were transferred to MRS broth liquid medium and cultured, and PCR amplification was performed using common 16s rRNA primers (upstream primer 27F: AGAGTTTG ATCCTGGCTCAG, downstream primer 1492R: GGTTA CCTTGTTACGACTT).

[0024] 2. Identification 2.1 16s rRNA sequencing The amplified product was sent for sequencing, and Bifidobacterium bifidum was selected by comparing its 16s rRNA gene sequences. In vitro screening was performed, and it was named Bifidobacterium bifidum ibiome001. Experimental method: Take 100 μL of bacterial solution, centrifuge at 12000 rpm for 2 minutes, discard the culture medium, and resuspend the bacterial cells in sterile ddH2O for use in PCR. The PCR system (20 μL) consists of 10 μL of 2× Taq Master Mix, 1 μL of primer 1 (341F), 1 μL of primer 2 (1492R), 6 μL of ddH2O, and 2 μL of bacterial suspension. PCR reaction program: 95°C for 3 minutes, 95°C for 15 seconds, 58°C for 15 seconds, 72°C for 30 seconds, steps 2-4 are 35x, and 72°C for 5 minutes. The PCR product of the 16S rRNA gene was sequenced, and the results are shown in SEQ ID NO.1.

[0025] 2.2 Microscopic examination of smear specimens Using a microscope, ibiome001 was examined in a smear at 40x magnification, and the microscopic images shown in Figure 1 were obtained. From the figure, it can be seen that ibiome001 is Gram-positive, exhibits short rod-like, slender rod-like, or spherical shapes, forms various morphologies such as branching and divergence, does not possess spores, and is non-motile.

[0026] 2.3 Photograph of a single colony After culturing ibiome001 in MRS medium for 48 hours, photographs were taken, and a single colony is shown in Figure 2. The colonies are white, circular, with evenly spaced edges and a moist surface.

[0027] 2.4 Hydrogen peroxide enzyme test and detection of biochemical reactions in sugar alcohol fermentation Transfer 300 μL of cryopreserved ibiome001 to 1 mL of MRS medium to revive the strain. Purify the liquid-cultured ibiome001 by streaking it onto MRS solid medium, select a single colony, inoculate it into 1 mL of MRS liquid medium, and culture for 24 hours. Then, gradient dilution of the liquid-cultured strain is performed and spread onto MRS solid medium for 72 hours. Next, a hydrogen peroxide enzyme test and detection of the sugar alcohol fermentation biochemical reaction are performed. Hydrogen peroxide enzyme test: Two to three drops of hydrogen peroxide enzyme reagent (purchased from "Qingdao Marine Biology," product number HB8650) were added to the ibiome001 colony. Since no bubbles were observed in the result, it was judged to be negative. Detection of sugar alcohol fermentation biochemical reaction: Using a sterile pipette tip, a single colony was transferred to a commercial bacterial biochemistry test ampoule (purchased from Qingdao Haibo Biological, product numbers GB057, GB102-1, GB104-1, GB176, GB178, GB188, GB189, GB193, GB195, GB196, GB197, GB199, GB200, GB201, GB202, GB203, GB204, GB206, GB207), and inoculated into an anaerobic culture at 37°C for 48 hours. The test results were interpreted according to the instructions of the reagent kit, as shown in Table 1. [Table 1] JPEG0007834388000001.jpg83170

[0028] 2.5 Whole Genome Sequencing ibiome001 was sent to a genetic testing company for whole-genome sequencing, and the resulting whole-genome sequences were assigned to ATCC 29521 (=JCM 1255, GenBank Assembly Accession: GCA_001025135.1), YIT 10347 (GenBank Assembly Accession: GCA_020892075.1), TMC 3115 (GenBank Assembly Accession: GCA_003573895.1), NCTC13001 (GenBank Assembly Accession: GCA_900637095.1), JCM 7004 (GenBank Assembly Accession: GCA_003573955.1), PRL2010 (GenBank Assembly Accession: GCA_000165905.1), HN002 (GenBank Assembly Accession). The sequences of Bifidobacterium bifidum strains such as Accession:GCA_016838705.1), BGN4 (GenBank Assembly Accession:GCA_000265095.1), BF3 (GenBank Assembly Accession:GCA_001281345.1), S17 (GenBank Assembly Accession:GCA_000164965.1), and S6 (GenBank Assembly Accession:GCA_003390735.1) were compared to obtain specific sequence fragments shown in SEQ ID NO.2-5, which are shown in Figure 3-7.

[0029] Example 2: Comparison of GPR120 activation by different Bifidobacterium bifidum. (1) HEK293 cell lines that stably express β-arrestin-TEV and tTA-luciferase are cultured in DMEM medium containing 10% fetal bovine serum and 1% penicillin / streptomycin. (2) Preparation of transfection mixture: Mix 200 ng / well of GPR120-tango plasmid with 400 ng of polyethylenimine (dissolved in 20 μL of DMEM) in 20 μL of DMEM and incubate at room temperature for 20 minutes. (3) After culturing the HEK293 cells from step (1) for two days (until approximately 90% fusion), add the transfection mixture from step (2) to the HEK293 cells from step (1). (4) 24 hours after transfection, replace the medium with 180 mL of DMEM medium containing 1% penicillin / streptomycin and 10 mM HEPES, and 20 μL of bacterial culture supernatant (Bb-1, Bb-2, Bb-3, or ibiome001, of which Bb-1, Bb-2, and Bb-3 are other Bifidobacterium bifidum screened in the laboratory, and their 16s rDNA sequences match SEQ ID NO.1). (5) After stimulating the bacterial culture supernatant for 24 hours, discard the supernatant and add 50 μL per well of Bright-Glo solution (Promega) diluted 20-fold with PBS containing 20 mM HEPES. (6) After incubation at room temperature for 20 minutes, fluorescence quantification is performed using Spectramax i3. As shown in Figure 8, the experimental results compared with the culture medium showed that ibiome001 had the strongest activating effect on GPR120, four times stronger than the control medium. The activating effects of all other Bifidobacterium bifidum strains were less than twice as strong, clearly demonstrating that ibiome001's activating effect on GPR120 is superior to that of other Bifidobacterium bifidum strains.

[0030] Example 3: Effects of the bacterial strain on mouse body weight, adipose tissue weight, lipolysis gene expression, oral glucose tolerance, fasting blood glucose, glycated hemoglobin, and plasma insulin. I selected C57BL / 6J (10 weeks old, male) mice, SPF grade, and purchased them from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. After the mice had adapted for one week, they were given a 60% high-fat diet (purchased from Medison, product number MD12033) and simultaneously given medication. The experiment was divided into four groups. (1) Control group: In this control group, 0.2 mL of PBS solution is administered to the stomach. (2) Bb group: 10 9Administer CFU Bifidobacterium bifidum ibiome001 into the stomach. (3) Bb+BI group: Bifidobacterium bifidum ibiome001 + Bifidobacterium longum (the strains are mixed in a 1:1 ratio, with a total of 10⁹ CFU colonies) is administered to the stomach. (4) 5mix (Ba+Bf+BI+Bb+Bp) group: A mixture of five types of Bifidobacterium bifidum, Bifidobacterium bifidum ibiome001 (Bb), Bifidobacterium longum (BI), Bifidobacterium adolescentis (Ba), Bifidobacterium faecale (Bf), and Bifidobacterium pseudocatenulatum (Bp) (the strains are mixed in a 1:1:1:1:1 ratio, with a total of 10⁹ CFU colonies).

[0031] 1. Effects on mouse body weight Before the experiment began, the mice were grouped according to their body weight, and their body weight was recorded weekly for a total of 13 weeks after the experiment started. Figure 9 shows the percentage change in body weight and the absolute value of the mice's body weight. As can be seen in Figure 9a, administering Bifidobacterium bifidum ibiome001 (Bb) to the stomach significantly suppressed weight gain in mice from week 4 onwards, and this effect continued until the end of the experiment. On the other hand, when combined with other Bifidobacterium bifidum strains, the effect of suppressing weight gain was not significant. Figure 9b shows that 13 weeks after administering Bifidobacterium bifidum ibiome001 to the stomach, the absolute body weight of the mice decreased by 5.53 g compared to the control group.

[0032] 2. Effects of fasting on blood glucose levels and oral glucose tolerance in mice In the 10th week of the experiment, the fasting blood glucose levels of the mice were measured, and an oral glucose tolerance test (OGTT) was performed. OGTT experimental method: The animals were fasted for 12 hours, blood was collected from the tail tip of the mice, and the fasting blood glucose level (at 0:00) of the mice was measured using a blood glucose test strip. Simultaneously, the mice were administered a glucose solution at a dose of 2 g / kg, and after administering glucose to the stomach, blood was collected from the tail tip at 30, 60, and 120 minutes, and the blood glucose level was measured. A curve of blood glucose change over time was drawn, and the area under the curve was calculated. The results of fasting blood glucose levels are shown in Figure 10: Administration of Bifidobacterium bifidum ibiome001 (Bb) into the stomach significantly reduced fasting blood glucose levels in high-fat diet-induced obese diabetic mice, but no improvement was observed when combined with other Bifidobacterium strains. The results of the oral glucose tolerance test (OGTT) are shown in Figure 11a: Gastrointestinal administration of Bifidobacterium bifidum ibiome001 (Bb) significantly reduced blood glucose levels 30 minutes after glucose loading (P=0.051) and significantly reduced the area under the curve of the oral glucose tolerance test (Figure 11b). However, there was no significant improvement when combined with other Bifidobacterium strains.

[0033] 3. Effects on mouse adipose tissue weight Thirteen weeks after administration, mice were fasted for 12 hours, and the mice were sacrificed to collect plasma and adipose tissue (mesenteral white fat, subcutaneous white fat, epididymal white fat, and brown fat). The adipose tissue was weighed, and the results are shown in Figure 12: Intragic administration of Bifidobacterium bifidum ibiome001 (Bb) significantly reduced the weight of subcutaneous white fat and mesenteric white fat in mice. Intragic administration of a combination of Bifidobacterium bifidum and Bifidobacterium longum (Bb+BI) only significantly reduced the weight of subcutaneous white fat in mice. There was no effect on the fat in any part of the mice administered a mixture of five types of Bifidobacterium intraglucanally.

[0034] 4. Effects on lipid degradation gene expression in mice RNA was extracted from the above-mentioned white adipose tissue, and the expression levels of lipolysis-related genes were measured by qPCR. The specific method is as follows. Tissue RNA extraction: RNA was extracted from animal tissues using a total RNA extraction kit (purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd., product number DP424). The specific procedure was followed by measuring the RNA concentration and purity using NanoDrop and agarose gel electrophoresis. Reverse transcription: 2 μg of total RNA from tissue was added to 2 μL of 5 × g DNA Buffer, replenished to 10 μL with RNase-Free ddH2O, briefly centrifuged, placed at 42°C, incubated for 3 minutes, then placed on ice for 10 minutes. Further additions included 2 μL of 10 × Fast RT Buffer, 1 μL of RT Enzyme Mix, and 2 μL of FQ-RT Primer Mix. The mixture was replenished to 20 μL with RNase-Free ddH2O, reacted in a 42°C water bath for 15 minutes, reacted at 95°C for 3 minutes, and stored at -80°C. qPCR: 2 μg of cDNA, 10 μL of SYBR stain, and 0.8 μL of primer were used, with the remaining volume supplemented with ddH2O (total reaction system: 20 μL). The reaction conditions were denaturation at 95°C for 10 minutes, followed by amplification (95°C for 15 seconds, 60°C for 1 minute, for a total of 40 cycles). Two subwells were created for each gene, and data processing was performed in 2 -Δ Δ Relative quantitative analysis was performed using CT. As shown in Figure 13, gastric administration of Bifidobacterium bifidum ibiome001 (Bb) increased the expression of the lipid-degrading genes ATGL and HSL, and there was a significant difference in the degree of increase in ATGL (P<0.05).

[0035] 5. The effects of glycated hemoglobin and plasma insulin in mice The plasma samples described above were collected, and the glycated hemoglobin and insulin content in the plasma were measured using reagent kits (purchased from Huamei Biotechnology, product numbers CSB-E08141m and CSB-E05071m). Glucose hemoglobin levels are the gold standard for blood glucose control. As shown in Figure 14, administering Bifidobacterium bifidum ibiome001 (Bb) into the stomach significantly reduced plasma glucose hemoglobin levels in high-fat diet-induced obese diabetic mice. However, when combined with other Bifidobacterium species, there was no effect on plasma glucose hemoglobin levels. As shown in Figure 15, administering Bifidobacterium bifidum ibiome001 (Bb) to the stomach significantly reduced the plasma insulin content in high-fat diet-induced obese diabetic mice, but administering a combination of Bifidobacterium bifidum and Bifidobacterium longum (Bb+BI) to the stomach had no effect on plasma insulin content.

[0036] In summary, administering Bifidobacterium bifidum ibiome001 (Bb) intragastricly significantly reduces body weight and white fat weight in high-fat diet-induced obese diabetic mice, and increases the expression of lipolytic genes ATGL and HSL. Furthermore, it significantly reduces fasting blood glucose, area under the curve in oral glucose tolerance tests, and plasma glycated hemoglobin and insulin content in mice. Bifidobacterium bifidum ibiome001 is a potentially functional strain for the treatment of metabolic syndrome, including obesity and diabetes, and its efficacy is superior to combinations with other Bifidobacterium bifidum strains.

[0037] The embodiments described above are merely descriptions of preferred embodiments of the present invention and do not limit the scope of the invention. Any modifications and improvements made by those skilled in the art to the technical solutions of the present invention, provided they do not deviate from the spirit of the invention, should all fall within the scope of protection defined in the claims of the present invention. [Industrial applicability]

[0038] Administering Bifidobacterium bifidum ibiome001 to the stomach significantly reduces body weight and white fat weight in high-fat diet-induced obese diabetic mice, and increases the expression of lipolytic genes ATGL and HSL. Furthermore, it significantly reduces fasting blood glucose, area under the curve in oral glucose tolerance tests, and plasma glycated hemoglobin and insulin content in mice. Bifidobacterium bifidum ibiome001 is a potentially functional strain for treating metabolic syndromes such as obesity and diabetes, exhibiting superior efficacy compared to combinations with other Bifidobacterium bifidum strains, and possessing clear industrial applicability.

Claims

1. Bifidobacterium bifidum ibiome001, The Bifidobacterium bifidum strain is characterized in that it is preserved at the Guangdong Provincial Microbial Species Preservation Center, located at the "5th Floor, Building 59, Dayuan, 100 Xianlie Middle Road, Guangzhou, Guangdong Province, Guangdong Provincial Academy of Sciences, Institute of Microbiology, Guangdong Province," with a preservation date of May 17, 2022, and preservation number GDMCC No. 62473.

2. A method for detecting Bifidobacterium bifidum ibiome001 according to Claim 1, wherein the strain of Bifidobacterium bifidum contains at least one specific gene fragment or a complementary fragment thereof in SEQ ID NO. 2-5.

3. A composition, The composition is characterized by comprising Bifidobacterium bifidum ibiome001 as described in claim 1, and a pharmaceutically acceptable carrier.

4. The composition according to claim 3, characterized in that the pharmaceutically acceptable carrier comprises one or more of the medically commonly used fillers, binders, wetting agents, disintegrants, lubricants, flavoring agents, diluents, and absorption enhancers.

5. The use of Bifidobacterium bifidum ibiome001 as described in claim 1, or the composition as described in claim 3 or 4, in the preparation of a functional bacterial agent or drug, The use of the functional antimicrobial agent or drug is characterized by its use in the prevention or treatment of one or more of the following diseases and symptoms of mammals (a) to (j). (a) Diabetes (b) Metabolic syndrome (c) Abnormalities in glycated hemoglobin (d) Abnormal insulin sensitivity (e) Abnormal fasting blood glucose levels (f) Abnormal oral glucose tolerance (g) Abnormal fasting insulin levels (h) Obesity (i) Weight gain (j) Increased weight of adipose tissue.

6. Use of Bifidobacterium bifidum ibiome001 according to claim 1, or the composition according to claim 3 or 4, in the preparation of a functional microbial agent or drug that activates GPR120.

7. Use of Bifidobacterium bifidum ibiome001 as described in claim 1, or the composition as described in claim 3 or 4, in the manufacture of a functional bacterial agent or pharmaceutical product that enhances the expression of lipolytic genes ATGL and / or HSL.

8. The use according to claim 5, characterized in that the diabetes is type 2 diabetes.

9. The use according to claim 5, characterized in that the mammal is a high-fat diet mammal.

10. Use of Bifidobacterium bifidum ibiome001 as described in claim 1, or the composition as described in claim 3 or 4, in the manufacture of food or nutritional supplements.

Images